Related Experiment Videos
Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind
Insights
Aerosolized ribavirin significantly improved outcomes for infants hospitalized with respiratory syncytial virus (RSV) lower-respiratory-tract disease. The antiviral treatment enhanced oxygen saturation and reduced viral shedding without adverse effects.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Lower-respiratory-tract disease caused by respiratory syncytial virus (RSV) is a common cause of infant hospitalization.
- Effective antiviral therapies for RSV infections remain a critical area of research.
Purpose of the Study:
- To evaluate the efficacy and safety of aerosolized ribavirin in treating hospitalized infants with RSV lower-respiratory-tract disease.
Main Methods:
- A double-blind, placebo-controlled study involving 33 infants hospitalized with RSV.
- Infants received either continuous aerosolized ribavirin or placebo for 3-6 days.
- Clinical severity scores, respiratory signs, arterial oxygen saturation, and viral shedding were monitored.
Main Results:
- Ribavirin treatment led to significant improvements in overall illness severity scores and lower-respiratory-tract signs.
- Arterial oxygen saturation was significantly higher in the ribavirin group compared to placebo.
- Viral shedding was reduced in infants treated with ribavirin, with no observed side effects or toxicity.
Conclusions:
- Aerosolized ribavirin is a safe and effective treatment for infants hospitalized with RSV lower-respiratory-tract disease.
- Ribavirin therapy demonstrated clinical benefits, including improved respiratory function and reduced viral load.
- No resistance to ribavirin developed in the RSV isolates during the study period.
Abstract:
We evaluated a new antiviral agent, ribavirin, in the treatment of infants hospitalized with lower-respiratory-tract disease from respiratory syncytial virus. Ribavirin or placebo was administered to 33 infants in a double-blind manner by continuous aerosol for three to six days. Seventeen infants were treated with placebo, and 16 with ribavirin. By the end of treatment, infants receiving ribavirin had significantly greater improvement in their overall score for severity of illness, in lower-respiratory-tract signs, and in arterial oxygen saturation. Viral shedding was also diminished in the treated groups as compared with the placebo group. No side effects or toxicity were associated with the aerosol therapy. Isolates of respiratory syncytial virus obtained from the infants over the course of therapy showed no change in sensitivity to ribavirin.